REQUEST A DEMO
Total
USD $0.00
Search more companies

C&R Research Inc. (Seoul) (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: C&R Research Inc. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center. The Company was established on June 18, 2020. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on September 23, 2020.

Headquarters
C R Bldg., 412, Yeoksam-Ro, Gangnam-Gu
Seoul; Seoul;

Contact Details: Purchase the C&R Research Inc. (Seoul) report to view the information.

Basic Information
Total Employees:
Purchase the C&R Research Inc. (Seoul) report to view the information.
Outstanding Shares:
Purchase the C&R Research Inc. (Seoul) report to view the information.
Registered Capital:
Purchase the C&R Research Inc. (Seoul) report to view the information.
Financial Auditors:
Purchase the C&R Research Inc. (Seoul) report to view the information.
Incorporation Date:
June 18, 2020
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
C R Healthcare Global (Singapore)
C R Research China (China)
Company Performance
Financial values in the chart are available after C&R Research Inc. (Seoul) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
13.49%
Total operating revenue
12.63%
Operating profit (EBIT)
-91.73%
EBITDA
-70.3%
Net Profit (Loss) for the Period
-83.29%
Total assets
7.3%
Total equity
14.15%
Operating Profit Margin (ROS)
-6.87%
Net Profit Margin
-5.87%
Return on Equity (ROE)
-2.06%
Debt to Equity Ratio
-17.49%
Quick Ratio
0.18%
Cash Ratio
-0.06%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?